Immunopharmacotherapy (Q20326): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Removed claim: co-financing rate (P837): 84.9999999482535 percent)
(‎Changed an Item)
Property / co-financing rate
 
85.0 percent
Amount85.0 percent
Unitpercent
Property / co-financing rate: 85.0 percent / rank
 
Normal rank

Revision as of 15:12, 19 March 2020

Project in Czech Republic financed by DG Regio
Language Label Description Also known as
English
Immunopharmacotherapy
Project in Czech Republic financed by DG Regio

    Statements

    country
    Czechia
    0 references
    EU contribution
    12,319,668.75 Czech koruna
    0 references
    492,786.75 Euro
    exchange rate to Euro
    0.04 Euro
    point in time
    10 January 2020
    0 references
    budget
    14,493,727.95 Czech koruna
    0 references
    579,749.118 Euro
    exchange rate to Euro
    0.04 Euro
    point in time
    10 January 2020
    0 references
    co-financing rate
    85.0 percent
    0 references
    start time
    1 May 2017
    0 references
    expected end time
    30 September 2022
    0 references
    beneficiary name (string)
    Univerzita Palackého v Olomouci
    0 references
    coordinate location

    49°35'41.89"N, 17°16'31.12"E
    0 references
    postal code
    77900
    0 references
    summary
    Realizací projektu budou vytvořeny odborné výukové materiály a zajištěno adekvátní personální zázemí pro akreditaci mezioborového DSP Imunofarmakoterapie efektivně spojujícího lékařskou imunologii a biologii s biotechnologií a technologií biokompatibilních nanopartikulárních dopravních systémů umožňující přípravu preventivních i terapeutických imunopreparátů. Absolventi budou schopni úspěšně řešit úkoly základního výzkumu, průmyslového výzkumu a experimentálního vývoje v imunofarmakoterapii. (Czech)
    0 references
    Through the implementation of the project, training materials will be created and adequate staffing resources are provided for the accreditation of the IORP-interbranch SAA, effectively combining medical immunology, and biocompatible biotechnology and biocompatible nano-sensitive transport systems enabling the preparation of both preventive and therapeutic immunoslides. Graduates will be able to successfully address the tasks of fundamental research, industrial research and experimental development in immunopharmacotherapy. (English)
    0 references

    Identifiers

    Czech Kohesio ID
    CZ.02.2.69/0.0/0.0/16_018/0002665
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q20326&oldid=2393204"